Positioned to capitalize on holiday shopping season
COLUMBUS, OH, Oct. 3, 2019 – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) (“GGB” or “the Company”) is pleased to announce that it has opened its 150th Seventh Sense® Botanical Therapy (“Seventh Sense”) CBD mall-based shop. The first Seventh Sense® shop opened in early February.
Watch Peter Horvath, CEO of GGB, discuss the growth of Seventh Sense from the Polaris Fashion Place location in Columbus, Ohio.
GGB will provide a sales update on the performance of Seventh Sense® shops and eCommerce on its earnings call for fourth quarter and fiscal year 2019 ended June 30. The call will occur on Thursday, October 24th, 2019. In the interim, the Company would like to share a progress update on the expansion of Seventh Sense®.
The 150 shops operate across 35 states and are expected to reach up to 200 locations by the start of the holiday shopping season
To date, nearly 20% of the customers in the consumer database have made a repeat purchase
Repeat online purchases occur on average every 31 days
There are over 350 product reviews to date with an average rating of 4.5 stars out of 5
The Seventh Sense® email consumer database grew 59% over August
SMS texting to consumers was launched on August 7th, enrollment grew 178% in the last 30 days
This month, Seventh Sense® will launch its first national media campaign, heavily focusing on digital and branded media partnerships. Activities will include editorial-focused media placements and unique out-of-home activations in key markets throughout the US.
Seventh Sense® shops retail high-quality botanical therapy CBD-infused personal care and beauty products at affordable prices. The product offering includes over 100 SKUs across bath, body, face, therapeutic, and sleep categories. To shop online, find a list of all retail locations and view consumer product reviews, please visit ShopSeventhSense.com and follow along on Instagram @seventhsensebotanicals.
About Seventh Sense Botanical Therapy Seventh Sense Botanical Therapy offers CBD-infused botanical body care using the finest ingredients on earth. Crafted with wellness in mind, Seventh Sense aims to make CBD an accessible part of self-care routines across the country. Discover the magic of CBD at shops across the country and online at ShopSeventhSense.com and on Instagram @seventhsensebotanicals.
About Green Growth Brands Inc. Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne. The Company also has a licensing agreement with the Greg Norman™ Brand to develop a line of CBD-infused personal care products designed for active wellness. Already driving the strongest sales per square feet in the cannabis industry, GGB is expanding its cannabis operations throughout the U.S its CBD presence at ShopSeventhSense.com, in malls across the country, at DSW and Abercrombie & Fitch stores—and that’s just the beginning. Learn more about the vision at GreenGrowthBrands.com.
Cautionary Statements:
Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; currency and interest rate fluctuations and other risks, including those factors described under the heading “Risks Factors” in the Company’s Annual Information Form dated November 26, 2018, which is available on the Company’s issuer profile on SEDAR.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release, including, but not limited to, the Company’s ability to execute on its growth strategy, the Company’s vision to become a multi-state operator with retail stores exceeding certain financial thresholds is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.
The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.
Thursday, October 3rd, 2019UncategorizedComments Off on $GGBXF Opens 150th CBD Shop and Provides Progress Update
Farmers in the United States have adopted the cultivation of hemp due to its increased prospects and abandoned mainstream crops such as soybeans which are ensnared in trade conflicts with other countries such as China. Therefore, in search of profitable alternatives, farmers have engaged in the widespread commercial planting of hemp.
Cannabidiol (CBD), a hemp compound which is a nonpsychoactive ingredient of marijuana, is at the center of the wellness industry in which beauty products and dietary supplement makers are using cannabidiol in the manufacturing process.
The Food and Drug Administration has not cleared the production of CBD infused foods and drinks, even though Congress legalized the growing of hemp. A California based manufacture of cannabidiol extraction machines, Delta Separations, estimates that $7.5 billion in hemp may spoil on farms.
Roger Cockroft, CEO of Delta Separations, attributed the estimated loss to lack of enough infrastructure to support processing the crop. He further added that the reluctance of banks to provide marijuana-linked businesses with loans is another prospect curbing the expansion process.
In 2018, Congress cleared the way for expanded planting of hemp after industrial hemp and CBD were legalized. According to the gathered data by the Department of Agriculture, farmers planted 142,691 acres of hemp this year. However, according to the Vote Hemp advocacy group, some farmers may be withholding the exact acreage planted from the government; therefore, the group estimates that the total acres planted to be 230,000.
An economist at Whitney Economics, Beau Whitney said the government is playing catch up with the hemp market as it is developing and expanding at a rapid rate.
A farmer in Delavan, Illinois, David Diekhoff has 1500 acres of hemp together with corn and soybeans. Diekhoff plans to look for a customer before harvesting the flowers from his plants.
Whitney Economics carried out a survey in July which found that 65% of hemp growers did not manage to find buyers for their crops. This forced them to enter into a contract with companies that are on the brink of financial difficulties.
The director of hemp markets at PanXchange says in the last few months, the price of some CBD products has dropped on the platform. For instance, the cost of winterized hemp oil is one-fifth of its January cost. The downward pressure on price may result in no payment for the farmers since the small processing companies will be having financial problems.
For the CBD extracted to be valid for use, farmers need to follow a specific order when harvesting hemp. The crop has to be dried after harvesting and before the extraction of CBD. The Whitney Economist says that since the farmers have no experience in harvesting the plant, they may leave it in the fields to dry, where it will be rained on and get mold — resulting in little or no CBD in the market which will eventually cause an increase in price.
In Yuma County, Arizona, Integrated CBD, which can process 1240 acres of hemp, has lined up buyers of CBD from the cosmetic and food industries.
In a phone interview, the CEO of Scottsdale, Patrick Horsman, said that the hemp business model requires growing, drying and extraction to work in cohesion. Therefore, as a farmer, you should be concerned if you do not have the processing and drying capabilities.
In another phone interview with the Executive Director of the Industrial Hemp Association in North Carolina, Blake Butler, said that many farmers shifted to hemp growth anticipating huge CBD profits. He further added that when farmers start to grow hemp for other uses, the industry will even out.
HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer
Do you have a questions or are you interested in working with HWN? Ask our Editor
Canopy Rivers (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, today provided details surrounding its investment in connection with a financing announced October 2, 2019. According to the update, Canopy Rivers has acquired ownership and control over (i) $13,243,000 principal amount of unsecured convertible debentures of TerrAscend Canada Inc. (the “Debentures”); and (ii) 333,723 common share purchase warrants of TerrAscend (the “Warrants”). The Debentures’ principal amount is convertible into fully paid and non-assessable common shares or exchangeable shares of TerrAscend at the holder’s option, or upon the occurrence of certain events, at a conversion price of $5.95 per share. The Debentures mature on October 2, 2024 and bear a per-annum interest rate of 6%.
Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem. For more information, visit the company’s website at www.CanopyRivers.com.
NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://cnw.fm/CNPOF
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask our Editor
SRAX (NASDAQ: SRAX), through its proprietary BIGtoken platform, has developed a consumer-managed data marketplace where consumers can own their own data and earn rewards for the release of that data. An article discussing the company reads, “Once consumers grant consent to allow businesses access to their data, BIGtoken sells that access in the form of anonymized segments; the platform can also remove access at any time. Once consent is granted, a mutually beneficial relationship is formed between SRAX and its customers. BIGtoken offers high-quality data that enables advertisers, for a premium, to have access to consumer-verified information for their campaigns. Moreover, consumers who sell access to their digital data receive compensation in the form of points, which they can redeem for cash or gift cards. . . . SRAX is growing numerous recurring revenue streams through its different platforms. Along with its BIGtoken platform, the company also offers its SRAX Platform, SRAX Social, SRAX IR, SRAX Auto, SRAX Fan and SRAX Shopper. SRAX is building technology that is creating proprietary data, in turn fostering long-term, recurring revenue.”
SRAX is a digital-marketing and consumer-data-management technology company. SRAX’s technology unlocks data to reveal a brand’s core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring revenue streams through its various platforms. Through the BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information, visit the company’s website at www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Skyline Medical, a subsidiary of POAI, continues to forge the standardization of waste fluid management with its sale of 10 systems in Rochester, NY.
The STREAMWAY System transforms the collection, measurement and disposal of healthcare waste fluid making it safer, easier and environmentally friendly.
POAI continues to impress, innovate with disruptive technological advancements in the healthcare industry.
MINNEAPOLIS, Oct. 02, 2019 — Predictive Oncology Inc. (NASDAQ: POAI) today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY® System for automated, direct-to-drain medical fluid disposal, has completed the sale of ten systems to the foremost teaching and research hospital in upstate New York. According to U.S. News and World Report, the 800+ bed hospital has among the best clinical programs in the country. The sale surpasses the company’s largest single hospital sale to date and is expected to generate 6000 procedures annually.
Skyline Medical’s patented, FDA-approved STREAMWAY System is the first truly continuous, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, surgery, urology, and cystoscopy procedures. The system has revolutionized the way healthcare facilities handle potentially infectious waste by connecting directly to facilities’ plumbing systems in order to automate the collection, measurement, and disposal of waste fluids. This minimizes human intervention, creating a safer system with improved compliancy with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines (http://nnw.fm/oaC78).
Additionally, by eliminating plastic waste in the form of canisters and evacuated bottles, the STREAMWAY System reduces overhead costs and minimizes environmental impact, eliminating the approximately 50 million potentially disease-infected canisters that wind up in landfills each year in the United States (http://nnw.fm/oQQ8d).
About Predictive Oncology Inc.
Predictive Oncology Inc. (NASDAQ: POAI) operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic, and biotech industries, and second, production of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal.
Forward-Looking Statements
Certain of the matters discussed in the press release contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (i) risks related to the recent merger with Helomics, including the fact that the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Company’s and Helomics’ existing businesses, distraction of management and diversion of resources; and the market price of the Company’s common stock may decline as a result of the merger; (ii) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (iii) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; Predictive Oncology’s ability to implement its long range business plan for various applications of its technology; Predictive Oncology’s ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of Predictive Oncology’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the SEC, which are available for review at www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of Predictive Oncology’s financial position. See Predictive Oncology’s most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.
Contact
Bob Myers, Predictive Oncology Inc.
651-389-4800
Wednesday, October 2nd, 2019UncategorizedComments Off on $POAI Sells 10 STREAMWAY® Systems to Prominent Teaching Hospital
Globally, industrial hemp is used in more than 250,000 products, and interest in this versatile plant doesn’t seem to have peaked just yet. For the first time, the World Ag Expo is going to feature a hemp pavilion where there will be space for exhibitors and a stage for seminars during the expo due to take place in February 2020.
The World Ag Expo held in California each year is seen as the defacto signal that the new agricultural season is about to begin, and that is why the organizers see this event as the best time to hold seminars and allow exhibitors to showcase what they have about hemp.
Now heading into its 53rd year, the World Ag Expo is undeniably the largest outdoor agricultural trade show organized annually in the world. The statistics of the last one held in 2019 are staggering.
For example, 102,800 people attended the event. These people were from 48 states across the U.S. and 65 countries. 1,400 exhibitors took part in the most recent event and next year is expected to attract even more. The available exhibition space is a mind-boggling 2.6 million square feet.
The expo is a platform for networking, business and education in one of the most productive agricultural counties in the United States.
During the 2019 World Ag Expo, the organizers worked and included six hemp panels to educate prospective industrial hemp farmers about the different options available to them. Each of the six stands was packed to capacity during each panel session, and this confirmed to the organizers that the expo was a good event at which hemp farmers can be given all the information that they need about this newly legalized crop.
While the crop has great potential, there are a number of growing pains that farmers have to contend with before they can reap from their harvest. These pitfalls include challenges in getting certified seed, the need for market contracts before a farmer puts the plants in the ground and the difficulties in getting financing from banks are some of the key obstacles that farmers have to find solutions to.
Those same issues will form the core of the discussions conducted during the seminars in the hemp pavilion next year. Exhibitors will also display some of the solutions available to the hemp industry.
Exhibition space in the hemp pavilion is now on sale and bookings can be made through the event organizers.
HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer
Do you have a questions or are you interested in working with HWN? Ask our Editor
According to an analysis performed by Tastewise, an artificial intelligence (AI)-powered food trend analysis company, people are searching for functional benefits in what they eat and drink, and that is why cannabidiol (CBD) has picked traction so quickly among consumers.
Tastewise was founded by a former executive at Google called Alon Chen, together with Eyal Gaon. The company analyzes billions of what they call “data points” taken from social media, home recipes and restaurant menus.
They use the findings of such analyzes to provide valuable insights on the ingredients playing a key role in shaping the food and beverages industry.
In its latest report, Tastewise highlights CBD and other ingredients that are having a monumental role in shaping the food and beverages landscape.
The report reveals that a third of all online conversations around food focus on the functional or health benefits of those foods. This could explain why food ingredients where health claims are made on the packaging attract more attention than those that don’t list any health claims.
Specifically for CBD, the report written by Tastewise indicates that there was a 286 percent increase in the number of people who consumed CBD products in order to improve their gut health.
In the last year, the number of people who wanted CBD products in order to improve their sleep rose by 201 percent, at least according to the data points tracked by the analytics company.
The number of people who discussed cannabidiol (CBD) as a food ingredient that improves the immune system increased by 138 percent from last year while those who wanted it for an energy boost increased by 70 percent over the same period.
It should be noted that most CBD on the market is extracted from industrial hemp, so it isn’t surprising that hemp oil registered a whopping 925 percent increase in the number of mentions by consumers looking to use it as a way to manage stress.
Other ingredients that were highlighted in this report include pea protein which saw a 542 percent rise in mentions as a wellness ingredient and celery whose user engagement statistics increased by 187 percent.
Experts say that this report shows how much pressure the FDA is going to be faced with as it formulates regulations for CBD products. Health claims seem to be integral to the success of this industry, and it would be enlightening to hear what CBD companies like Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) and Hemptown USA suggest as ways to keep the industry growing while making limited claims about the health benefits of this cannabinoid.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
NEW YORK, Oct. 02, 2019 — via NetworkWire – GP Solutions Inc. (OTC: GWPD), a leading developer of highly innovative, automated micro-farms under the trade name “GrowPods,” today announces it has selected the corporate communications expertise of NetworkNewsWire (“NNW”).
GP Solutions provides innovative, environmentally optimized systems for growing high quality specialty leafy crops without pesticides, harmful chemicals, pathogens or contaminants. Each GrowPod utilizes the most recent technology using PROLIFIC soil-less growth medium or hydroponic growing technology to allow year-round growing capable of producing predictable yields and maximizing growers return on investment.
Headquartered in Colton, California, GP Solutions produces custom container farms for growers, farmers, restaurants, hotels, casinos, entrepreneurs and investors located throughout North America.
NNW is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility. As part of the Client-Partner relationship with GP Solutions, NNW will leverage its investor-based distribution network of over 5,000 key syndication outlets, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the company.
“The engineering behind GP Solutions’ GrowPod container farms provides year-round farming anywhere in the world. This capability addresses the issues of providing a clean and safe food supply, reducing world hunger, maximizing crop yields, and offering a rapid and inexpensive pathway for entrepreneurs and businesses to enter multiple agricultural sectors,” states Sherri Franklin, Director of Client Solutions for NNW. “As the company focuses on expanding its market reach and application, we will execute a corporate communications campaign that places its strategy and accomplishments in front of the investment community.”
About GP Solutions
GrowPod Solutions, Inc. is the developer of highly innovative automated micro-farms trade named “GrowPods.” GrowPods are a modular, stackable and mobile vertical growing environment specifically engineered to maximize yield and automation. GP Solutions offers a fully insulated, food-grade shipping container specifically modified to provide the optimum controlled environment for growing a wide range of horticultural and agricultural products in all environments and climates. With the company’s combination of hydroponic and certified organic soil systems, clients can produce a significantly higher yield that grows faster, healthier and more consistently. For more information, visit the company’s website at www.GrowPodSolutions.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets, (3) enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
TORONTO, Oct. 2, 2019 – Canopy Rivers Inc. (“Canopy Rivers“) (TSX: RIV, OTC: CNPOF), a venture capital firm specializing in cannabis, has completed a US $10 million investment (the “Investment“) in TerrAscend Canada Inc. (“TerrAscend Canada“), a subsidiary of its portfolio company TerrAscend Corp. (“TerrAscend“) (CSE: TER, OTCQX: TRSSF). The investment includes the purchase of 13,243 units, with each unit consisting of: (i) one unsecured convertible debenture of TerrAscend Canada with a principal amount of CA $1,000 (the “Debentures“), and (ii) 25.2 common share purchase warrants of TerrAscend exercisable until October 2, 2024 (the “Warrants“).
TerrAscend is the first and only cannabis company with sales in Canada, the U.S., and Europe. TerrAscend’s international cannabis portfolio includes a robust research and development platform, domestic and international cultivation, processing, and distribution facilities, and a portfolio of medical and adult-use branded cannabis products, and is one of a select group of industry operators to have been recognized with a European Good Manufacturing Practices (“EU GMP”) certification. TerrAscend is also an active participant in the Canopy Rivers ecosystem, with significant agreements in place with Canopy Rivers portfolio companies PharmHouse Inc. and James E. Wagner Cultivation Corporation.
“We think TerrAscend is uniquely positioned to meet the evolving consumer demands in the three largest cannabis markets worldwide,” said Narbe Alexandrian, President & CEO of Canopy Rivers. “We strongly believe in TerrAscend’s ability to execute on its global strategy, market a diversified brand portfolio, and build on its recent acquisitions, and this additional investment is an affirmation of that belief.”
“We are privileged to have the continued confidence and support of Canopy Rivers, one of the preeminent investment firms specializing in cannabis,” said Michael Nashat, CEO of TerrAscend. “This growth capital enables us to accelerate our organic and acquisition-driven investments in our key markets across the globe, as we execute our strategic vision of being a truly global cannabinoid company.”
Canopy Rivers, along with Canopy Growth Corporation, first invested in TerrAscend in November 2017. In October 2018, both parties restructured their investment in TerrAscend. This restructuring enabled TerrAscend to pursue strategic international transactions in the cannabis space while ensuring all parties remained compliant with industry and securities regulations.
Transaction Overview
The Debentures will bear interest at a rate of 6.0% per annum and will mature on October 2, 2024. Each Debenture will be convertible into common shares or exchangeable shares in the capital of TerrAscend at the option of Canopy Rivers or upon the occurrence of certain events at a conversion price of CA $5.95, a 10% premium to the 5-day VWAP ended September 30, 2019. TerrAscend fully and unconditionally guarantees TerrAscend Canada’s obligations under the Debentures, such guarantee to be enforceable by the payment of the equivalent value in exchangeable shares of TerrAscend or, upon the occurrence of certain events, in common shares or in cash.
Each Warrant will entitle Canopy Rivers to acquire one common share of TerrAscend, at an exercise price of CA $6.49, a 20% premium to the 5-day VWAP ended September 30, 2019, and such Warrants will be exercisable following changes in U.S. federal laws regarding the cultivation, distribution or possession of marijuana, the compliance of TerrAscend with such laws, and the approval of the securities exchanges upon which Canopy Rivers is listed.
Net proceeds from the Investment will be used by TerrAscend Canada for general corporate purposes and will not be used in connection with cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States.
About Canopy Rivers
Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.
Forward-Looking Statements
This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the terms of the Investment; the conversion of the Debentures into common shares or exchangeable shares of TerrAscend; Canopy Rivers’ right to acquire common shares of TerrAscend pursuant to the Warrants; the use of proceeds from the Investment; management’s belief thatTerrAscend is uniquely positioned to meet evolving consumer demands in the three largest cannabis markets worldwide; management’s belief in TerrAscend’s ability to execute on its global strategy, market a diversified brand portfolio, and build on its recent acquisitions; the expectation that the Investment will enable TerrAscend to accelerate its investments in key markets; and expectations for other economic, business, and/or competitive factors.
Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; the ability of Canopy Rivers to exercise the Warrants in order to acquire common shares of TerrAscend; changes in the use of proceeds from the Investment; TerrAscend’s ability to complete and integrate acquisitions and other global strategies and to market a diversified brand portfolio; changes in consumer demands and TerrAscend’s ability to meet such demands; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ annual information form dated July 15, 2019, filed with the Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
Wednesday, October 2nd, 2019UncategorizedComments Off on $CNPOF $RIV.V Invests Additional US $10 Million in TerrAscend
SAN DIEGO, Oct. 1, 2019 — Youngevity International, Inc. (NASDAQ: YGYI), a leading multi-channel lifestyle company, today announced the timing for the payment of its declared regular monthly dividend of $0.203125 per share of its 9.75% Series D Cumulative Redeemable Perpetual Preferred Stock (NASDAQ:YGYIP) for September 2019. The dividend will be payable on October 15, 2019 to holders of record as of September 30, 2019. The dividend will be paid in cash.
About Youngevity International, Inc.
Youngevity International, Inc. ( NASDAQ : YGYI ), is a multi-channel lifestyle company operating in 3 distinct business segments including a commercial coffee enterprise, a commercial hemp enterprise, and a multi-vertical omni direct selling enterprise. The Company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity, YGYI offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. For investor information, please visit YGYI.com. Be sure to like us on Facebook and follow us on Twitter
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Contacts:
Youngevity International, Inc. Dave Briskie
President and Chief Financial Officer
1 800 982 3189 X6500
The company hosted site visits with analysts from Canada and the United States
TGOD is strategically creating a sustainable footing in Canada, Europe, the Caribbean and Latin America
The company is dedicated to making life better, both locally and globally
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) uses certified organic, craft growing practices to cultivate high-quality organic medical cannabis. The company consistently holds to the highest levels of excellence as it strives to become the global leader in organic cannabis solutions. Through innovative tech and low-cost power solutions, TGOD is able to provide cost-efficient premium cannabis.
On September 19-20, the company hosted site visits for approximately 25 analysts at its Hamilton and Valleyfield facilities (http://cnw.fm/aC9Ly). This marked the first time that TGOD has shared to this extent its Canadian flower production ramp-up, the unveiling of the cannabis 2.0 portfolio and a sampling of noninfused beverage formulations, which were well received. Management also provided an update on the phased facility’s construction completion.
Along with management, TGOD’s growing operations team introduced analysts from Canada and the United States to the company’s cultivation differentiator, proprietary technology and horticultural practices. Analysts walked the grounds of the combined 1,476,000 sq. ft. purpose-built facilities and received updates on the completion of Hamilton’s hybrid greenhouse and Valleyfield’s anticipated first harvest. Total annual production capacity at Hamilton is now 17,500 kilograms; Valleyfield will have approximately 65,000 kilograms of annual run rate capacity turning on in the fourth quarter of 2019 (http://cnw.fm/Jkn4a).
“We are doing something no other producer has done before, growing premium certified organic cannabis at scale,” TGOD CEO Brian Athaide stated in a news release (http://cnw.fm/Z6NlA). “By leveraging our proprietary growing methods, purpose-built facilities and industry-leading horticultural team, we are creating a wide economic moat within the premium organic segment… We are extremely proud to showcase the hard work that went into designing and building these state-of-the-art facilities as well as our cannabis 2.0 portfolio.”
TGOD is strategically creating a sustainable footing in Canada, Europe, the Caribbean and Latin America. The company’s approach is unique and includes operating cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. Experience gained from previous business ventures has led TGOD to focus on:
Cultivating organically and at scale;
Ensuring logistical and infrastructure controls;
Utilizing strategic partnerships with experts in their fields; and
Growing its world class CPG senior management team.
TGOD is committed to making life better and nurturing a community that respects a sustainable way of life. This philosophy is at the heart of everything the company does, both on-site and off. Although the company has eyes on esetablishing itself as the global leader in certified organic cannabis, TGOD has not forgotten its roots. The company’s goal is to also create a positive economic impact in local towns and communities across Canada. Following this mission, TGOD produces more than just cannabis. Community Farm, a plot of land within the Hamilton Ancaster Facility Grounds, grows organic food and provides it to local food-donation programs. More than 2,000 pounds of high-quality food has been given to Hamilton food-share programs, a further example that The Green Organic Dutchman is 100 percent committed to ‘Making Life Better’, both at home and around the world.
For more information, visit the company’s website at www.TGOD.ca
NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://cnw.fm/TGODF
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask our Editor
Data from Analysis of Cancer Tissue Proteins Generated from Novel Workflow Could Lead to Improvement in the Clinical Management of Gynecological Cancers
SOUTH EASTON, Mass., Oct. 01, 2019 — via OTC PR WIRE – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced the Company’s patented pressure cycling technology (“PCT”) platform was featured as an integral part of a new, innovative workflow for the analysis of proteins from cancer biopsy samples. This workflow was presented in a plenary session at the Annual Meeting of the International Gynecologic Cancer Society (“IGCS”) on September 21, 2019 in Rio de Janeiro, Brazil. The mission of the IGCS is to improve the care and outcomes for women with gynecologic cancer worldwide through education, training and public awareness.
According to Dr. Larry Maxwell, MD, gynecologic oncologist and Chair of OB-GYN at Inova Fairfax Hospital, “the conventional use of chemotherapy in ovarian cancer treatment is being rapidly replaced by biologic therapeutics that target the cancer (the “seed”) and also the micro-environment (the “soil”) in which it grows. Being able to collect small tissue specimens and characterize them across multiple genomic and proteomic platforms will enable us to markedly enhance our ability to develop companion diagnostics and prognostics as well as identify targets for future therapeutic strategies. Technology provided by Pressure BioSciences has become an essential requirement for our novel workflow in meeting our goals.”
Gynecologic malignancies include ovarian, uterine, and cervical cancers. Together they are responsible for approximately 35,000 deaths annually in the United States with ovarian cancer ranking fifth in cancer deaths among women (Aurora Healthcare and the Centers for Disease Control and Prevention). According to Acumen Research and Consulting (2018), the global ovarian cancer diagnostics market alone is forecasted to grow at a CAGR around 5.9% over the forecast time frame and reach around US $1.8 billion by 2026. New, improved methods to detect these cancers are vitally needed to support the design and development of better treatments through enhanced precision medicine. The IGCS is committed to addressing this critical issue.
Dr. Thomas Conrads, a nationally acclaimed protein chemist, is the Senior Director of Women’s Health Research at the Inova Women’s Hospital. Dr. Conrads’ group was invited to present their innovative workflow for analyzing cancer tissue proteins at the IGCS meeting. The presentation titled Interim Analysis of Ovarian Cancer by the US National Cancer MOONSHOT’S Tri-Federal (DOD/NCI/VA) Applied Proteogenomic Organizational Learning and Outcomes (APOLLO) Research Network, was made by Dr. Maxwell. Data demonstrated the feasibility of proteogenomic characterization of known-patient tumors for specimen preparation in support of large-scale analyses in the U.S. Cancer Moonshot’s APOLLO program. This program focuses on genetic sequencing and proteomic analysis of tumors in order to develop clinically actionable molecular panels for precision medicine and personalized health.
The novel workflow developed by Dr. Conrads and his colleagues integrates the Leica Microsystems’ laser microdissection (LMD) platform and PBI’s PCT platform, enabling micro-scale quantitative proteomics and phosphoproteomics on a ThermoFisher Scientific mass spectrometry (MS) instrument. LMD is a state-of-the-art method for precise excision of cells from biopsy tissues at microscopic scale by a laser. Excised cells are delivered directly into PBI’s MicroTubes for critical sample preparation, including rapid and efficient high-quality cellular protein release. Proteins are then analyzed by mass spectrometry (MS), the global method-of-choice for high throughput and comprehensive protein analysis.
Dr. Conrads commented: “We are very pleased to have been invited to present the results of our work in gynecologic cancer research in a plenary session at this important international meeting. The novel workflow developed by our group integrates and operationalizes state-of-the art techniques: laser microdissection (LMD), pressure cycling technology (PCT), and mass spectrometry (MS) to improve our understanding of the complex tissue microenvironment and, in this case, to enable identification of biomarkers associated with women’s cancers. We believe that the insights we gain from applying this novel workflow will result in significant improvements in the clinical management of gynecologic cancer.”
Dr. Nate Lawrence, Senior Consultant to PBI, said, “Precision medicine promises a paradigm shift in the diagnosis and treatment of disease. This shift is highly dependent on the generation and evaluation of high-quality data generated during comprehensive analyses of each patient’s tumor samples. Although critical to precision medicine the generation of such data from biopsy samples has been difficult to date, as it requires the integration of multiple and varied laboratory processes, including tissue extraction, critical sample processing, and analysis. The innovative workflow developed by Dr. Conrads and his colleagues combines the precision of Leica Microsystems’ state-of-the-art LMD system on the frontend with the superior analytical capabilities of Thermo Scientific’s mass spectrometer on the backend. In the middle, integral to connecting these two superb instrument systems, is the speed, robustness, reproducibility, and versatility of PBI’s PCT Barocycler system.”
Mr. Richard T. Schumacher, President and CEO of PBI, concluded: “We were delighted to see PBI’s Barocycler system featured in its pivotal position in this important new tumor processing workflow that Dr. Conrads and his colleagues have presented: the critical enabling step after LMD excision and before MS analysis. Based on results to date, we believe that the number of laboratories worldwide performing laser microdissection followed by mass spectrometric analyses will increase at a steady but significant rate, that our Barocycler system will remain a critical part of this workflow, and that the adoption of this novel new workflow should result in a measurable increase in Barocycler sales over the coming months and years.”
About Inova
Inova is Northern Virginia’s leading nonprofit healthcare provider, recognized in 2019 by U.S. News & World Report which named the Inova Fairfax Medical Campus the #1 hospital in the Washington, DC, region with four of Inova’s five hospitals receiving five-star rankings from the Centers for Medicare and Medicaid Services. Our mission is to provide world-class healthcare – every time, every touch – to each person in every community we have the privilege to serve. Inova’s 18,000 team members serve more than 2 million individuals annually through an integrated network of hospitals, primary and specialty care practices, emergency and urgent care centers, outpatient services and destination institutes. Inova is home to Northern Virginia’s only Level 1 Trauma Center and Level 4 Neonatal Intensive Care Unit. Its hospitals have a total of 1,800 licensed beds.
Four of Inova’s five hospitals have received five-star rankings from the Centers for Medicare and Medicaid Services (CMS) and three are ranked in the top 10 in the region by US News and World Report; they are the only hospitals in the Washington, DC region to have earned the highest rating from CMS and straight “A” grades from Leapfrog Hospital Safety Grades. Inova connects researchers, clinicians and empowered consumers to improve patient care, enhance prevention and encourage wellness. More information and statistics about Inova can be found at inova.org.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.
Investor Contacts:
Richard T. Schumacher, President and CEO, (508) 230-1828 (T)
Nathan P. Lawrence, Ph.D., Senior Consultant, (508) 230-1829 (F)
Tuesday, October 1st, 2019UncategorizedComments Off on $PBIO Proprietary PCT Platform Fills Pivotal Role for Tumor Analyses in Novel Workflow
The WMCE (West Michigan Cannabis Expo) will be all things marijuana. It is a two-day event, that will be held at DeltaPlex Arena in Grand Rapids. The event which will be having 60 booths plus is a perfect opportunity for consumers, businesses and other professionals in the cannabis industry to showcase their products and services. It is also an avenue for learning more about the marijuana industry.
The expo also aims to help businesses to develop new leads, strengthen their relationship with their clients and customers, and market their organization.
Some of those who will be in attendance include a hemp product company, cannabinoids retailers, equipment retailers, consumers and growers, as well as legal and accounting professionals.
The WMCE commences on Saturday 5th October. The event opens at 10 a.m and will end at 5 p.m. October 6th is the last day of the expo, and it will be open from 10 a.m to 4 p.m at the DeltaPlex Arena.
DeltaPlex director of events development, Chris Hudson says that business-oriented people expected to attend the event are about 60 percent while the remaining 40 percent comprises of cannabis consumers and people who would like to learn more about the industry.
In November 2018, Michigan legalized marijuana for personal use while medical marijuana was legalized in 2008. The legislation governing recreational marijuana provides that you must be 21 years or older to purchase, use or cultivate marijuana.
According to Hudson, the WMCE was organised after significant growth was observed that in the sector since the legalization of recreational marijuana as people from other states came to Michigan to get their fix. More so, businesses and individuals seeking to join the industry have many questions, and the Expo would help answer and educate them on how to join the marijuana industry. The expo would also help them gain resources such as machines required to make and extract marijuana products.
During the expo, there will be cannabis-cooking demonstrations, seminars on marijuana licensing and banking with cannabis, cannabis medicines displays, and extracts.
The cost of a ticket is $15 for one day, but if you want to attend both days, you will have to pay $25. There is also an upgraded ticket that costs $50, which allows you to participate in a mixer on Saturday at 5.30 p.m. The mixer is for adults who are 21 years and above.
THC products are not allowed into the expo because the state will accept recreational business applications in November.
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW420? Ask our Editor
The main subsidiary of POAI partnered with Genomics England for the groundbreaking UK 100,000 Genomes Project
POAI is positioned on the cutting edge of future cancer treatments
The company’s AI-driven platforms are improving cancer patient outcomes and setting a new standard in the industry
For years, cancer treatment has involved human beings playing the role of guinea pigs. Oncologists have become quite adept at diagnosing specific types of cancer, but they mostly lack the data to know which drugs will be most effective in fighting patients’ specific cancer types. Patients leave doctors’ offices hopeful but worried, gambling their recovery on the power of the prescription they received. This is the cancer treatment of today. However, the future of cancer treatment could be transformed with the innovative technologies of Predictive Oncology Inc. (NASDAQ: POAI), a company developing highly customizable assessment methods for cancer patients to guide personalized treatments.
As part of Predictive Oncology’s commitment to determining the best pathways for more individualized and effective cancer treatment, one of its main subsidiaries – Helomics – partnered with the UK 100,000 Genomes Project (“UK100K”) in a research study focused on driving precision medicine to help conquer ovarian cancer. The UK100K initiative couples whole genome sequencing of National Health Service (NHS) patients with cancer and other diseases to rich clinical data on drug treatments and outcomes. Helomics’ study centers around utilizing this data to continue improving the effectiveness of its artificial intelligence (AI)-based precision oncology models to drive both the individualization of therapy (right drug for the right patient) as well as the discovery of new treatments. Over the long term, Helomics intends to seek approval to use its precision oncology models as part of the NHS for ovarian cancer treatment.
“The promise of precision oncology is therapy tailored to the patient’s own cancer, yet the reality is that while we can identify alterations in the DNA of the patient’s tumor, most of these mutations are not actionable with current drugs,” Dr. Mark Collins, chief innovation officer at Helomics, stated in a news release (http://nnw.fm/5ZIwR). “The goal of this project is to combine genomic profiling of the patient tumor and the drug response of the patient from the Genomics England data with Helomics’ unique data set, utilizing the power of machine learning to create a ‘virtual’ model of the tumor.”
Collins described his team’s ability to use Helomics’ model to guide oncologists in selecting appropriate drugs to best treat each patient. Moving forward, the company seeks to partner with pharmaceutical firms to develop the “next generation” of precision therapies using these models.
“We’re delighted to work with Helomics and its precision oncology products to maximize the benefits to patients,” added Genomics England Chief Commercial Officer Joanne Hackett. “Helomics will collaborate with other companies at the forefront of genomics and technology to ensure that we turn research findings into treatments, diagnostic, and benefits for patients as soon as possible.”
As a result of the UK 100,000 Genomes Project, the United Kingdom became the first nation in the world to apply whole-genome sequencing at scale in direct health care, as well as providing access to high-quality, de-identified clinical and genomic data. This data is crucial for improving outcomes for patients and has established a difference between patients who are able to beat their cancers and those who are not.
As a result of its valuable data set and increasingly effective predictive models, Predictive Oncology is on the cutting edge of what could soon be seen as the norm for cancer treatment.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
A Toronto-based cannabis company announced on Tuesday that it had signed an agreement with a Chinese partner allowing the Canadian company to grow and process industrial hemp on 17,000 acres in China.
Pure Global Cannabis, the Canadian company, signed this agreement with a Chinese company called KMT-Hansa Corp. KMT currently holds licenses to grow and process hemp on 17,000 acres in China, and they are teaming up with Pure Global to pull it off.
Under the terms of the agreement, Pure Global will be responsible for providing the technology, know-how and the plant genetics required for the success of the project. Pure Global will also take charge of distribution and sales of all the products that are made during the execution of the joint project.
The Canadian company has also been tasked with designing the extraction, processing and manufacturing facilities that comply with Good Manufacturing Practices (GMP).
Another seller or distributor for the products made can only be sourced once Pure Global declares that it is waiving its right to this component of the business.
KMT-Hansa Corp. will take charge of making sure that all the necessary licenses and permits are secured and maintained with all the relevant Chinese government authorities.
Malay Panchal, the President and CEO of Pure Global, revealed in a press statement that he was excited that Pure Global had managed to be the first Canadian company to secure a partnership that enabled it to put together such a large-scale project in China.
Panchal believes that the entire team at KMT shares Pure Global’s goal of coming up with high-quality agricultural products that are made using the best cutting-edge technology currently available.
This agreement is viewed by both parties as a stepping stone to other bigger international production agreements between the two entities. The two companies are therefore committed to moving quickly to address the needs of a rapidly growing market for CBD products.
Pure Global and KMT plan to sell CBD isolates and consumer products throughout Asia as well as 50 international markets where CBD is legal.
Panchal also revealed that this is an exciting time for Pure Global because they have not only managed to secure the deal with KMT, but have also received a cannabis oils sales license from Health Canada.
Experts believe that partnerships such as those entered into by Pure Global Cannabis and KMT-Hansa Corp. provide impetus to other hemp companies, such as Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) and Earth Science Tech Inc. (OTCQB: ETST), to work harder and increase their international footprint in order to tap the global market for hemp-derived products.
About HempWireNews
HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer
Do you have a questions or are you interested in working with HWN? Ask our Editor
MINNEAPOLIS, Sept. 30, 2019 — Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced that its secured promissory notes that were due September 28, 2019 have been repaid or extended. On September 27, 2019, the Company repaid the remaining principal and interest balance of $478,590 on one of such notes. On the same date, the Company obtained a new investment of $700,000 from a private investor in exchange for a new 8% secured promissory note due on March 27, 2020 with an original principal amount of $847,500. The Company also issued 88,574 shares of common stock and a 682,368 share warrant to the new investor.
In addition, on September 27, 2019, the Company amended the other outstanding note to extend the maturity date from September 28, 2019 to December 31, 2019. The outstanding principal amount of the note was increased by $120,000 to a current principal amount of $1,789,104, and the Company issued 150,000 shares of common stock to the investor in connection with certain amended terms.
About Predictive Oncology Inc.
Predictive Oncology Inc. (NASDAQ: POAI) operates in two business areas: first, applying artificial intelligence to personalized medicine and drug discovery to provide personalized medicine solutions for patients and clinicians as well as clients in the pharmaceutical, diagnostic, and biotech industries, and second, production of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal.
Forward-Looking Statements
Certain of the matters discussed in the press release contain forward-looking statements that involve material risks to and uncertainties in the Company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include (i) risks related to the recent merger with Helomics, including the fact that the combined company will not be able to continue operating without additional financing; possible failure to realize anticipated benefits of the merger; costs associated with the merger may be higher than expected; the merger may result in disruption of the Company’s and Helomics’ existing businesses, distraction of management and diversion of resources; and the market price of the Company’s common stock may decline as a result of the merger; (ii) risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns; and (iii) other risks and uncertainties relating to the Company that include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; sales cycles that can be longer than expected, resulting in delays in projected sales or failure to make such sales; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance, if our product is not accepted by our potential customers, it is unlikely that we will ever become profitable; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; Predictive Oncology’s ability to implement its long range business plan for various applications of its technology; Predictive Oncology’s ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of Predictive Oncology’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the SEC, which are available for review at www.sec.gov. This is not a solicitation to buy or sell securities and does not purport to be an analysis of Predictive Oncology’s financial position. See Predictive Oncology’s most recent Annual Report on Form 10-K, and subsequent reports and other filings at www.sec.gov.
Contact
Bob Myers, Predictive Oncology Inc.
651-389-4800
Monday, September 30th, 2019UncategorizedComments Off on $POAI Repayment or Extension of Promissory Notes
In a press conference on Wednesday, Tom Wolf, Pennsylvania Governor accompanied by Lt. Gov. John Fetterman, announced his support for the legalization of adult-use recreational marijuana. In his announcement, he included the final report from Lt. Governor John Fetterman’s statewide tour on recreational marijuana legalization. He also proposed the next steps to be taken after reviewing the input submitted by the citizens from the 67 counties who attended their listening sessions or reverted via their online platform.
In his announcement, Governor Wolf said that Lt.Governor Fetterman fulfilled his promise of touring all the 67 counties in Pennsylvania to get the opinion of the citizens regarding the legalization of adult-use recreational marijuana. Moreover, the majority of the feedback received was in favor of recreational marijuana legalization.
Lt. Governor John Fetterman invited the public, media companies and local officials to the tour stops in each county, where the attendees indicated their interest in the bill by a show of hands.
The report comprises of two parts. The first part looks at the volume of messages sent to the online platform hosted on the governor’s website, the comments made on the platform and comment cards collected at the tour stops, as well as any additional message received by the Lt. Gov Fetterman in other formats.
During the announcement, the Lt. Governor voiced his appreciation for the Pennsylvania citizens who attended his tours and those who submitted their comments either physically or online. He also assured the Pennsylvanians that they will do their best to bring into effect the proposed changes.
Apart from announcing the report, the Pennsylvania Governor and Lt. Governor called for the legislature to get a bill that decriminalizes non-violent and cannabis-related offenses to the governor’s desk. They also announced that they are seeking justice by expunging non-violent and small cannabis-related crimes convicted in the past. Finally, they are asking the General Assembly to debate and pass the bill legalizing recreational marijuana.
Since the majority of Pennsylvania residents are in favor of recreational marijuana legalization, Governor Wolf says that he is looking forward to accomplishing many missions together. This includes the criminal justice reform that he is proposing as it will positively affect the people of Pennsylvania.
In his final remarks, Governor Wolf expressed his gratitude to Lt. Gov. John Fetterman for touring the 67 counties and conducting the research. More gratitude was directed towards the Pennsylvanians who attended the tour stops, wrote messages or called the headquarters to voice their opinion.
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW420? Ask our Editor
Cannabis-focused research and development company The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a leading producer of premium certified-organic cannabis, is on a mission to meet the growing demand for organic cannabis in Canada. An article discussing the company reads, “Recently, TGOD received a 100% organic rating from Toronto-based Corporate Knights magazine (http://cnw.fm/9jgNC). The company is one of the few in Canada licensed to cultivate organic cannabis. The Green Organic Dutchman is a pioneer in shifting from indoor farming to greenhouse cultivation, making use of solar energy and cutting electricity costs by up to 90%. Companies leading this effort are using glass-roofed greenhouses equipped with the latest high-tech equipment to produce ‘sun-grown’ organic cannabis (http://cnw.fm/MP6Ug).”
The Green Organic Dutchman Holdings is a publicly traded, premium, global, organic-cannabis company with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic-hemp, CBD-oil operations in Canada and, through its wholly owned subsidiary HemPoland, distributes premium-hemp CBD oil in the EU. The company grows high-quality, certified-organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned global capacity of 219,000 kgs. and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. For more information, visit the company’s website at www.TGOD.ca.
NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://cnw.fm/TGODF
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask our Editor
The cannabis space is targeting some relatively remarkable growth estimates, with analysts routinely jacking up forecasts. But two dynamics have made it increasingly difficult for investors in the space: the increasing supply along with demand to suit the process of legislative and mainstream adoption has pressured cannabis pricing, and the enthusiasm of investors along the way has created some valuation issues that have led to significant pain for poorly timed entries.
That leaves us with a classic stockpicker’s market in the pot stock space. We review several candidates to aid in your analysis: Tilray Inc (NASDAQ:TLRY), Medicine Man Technologies Inc (OTCMKTS:MDCL), and OrganiGram Holdings Inc (NASDAQ:OGI).
Tilray Inc (NASDAQ:TLRY) has been a controversial name because the short-squeeze was so dramatic in the opening months of the stock’s listed trading, and yet it has now fallen in such a shocking manner, with the stock’s current woes being directly related to massive debt servicing costs from convertibles – a worse situation one cannot imagine for a company at this stage.
According to company materials, the company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. was incorporated in 2018 and is headquartered in Nanaimo, Canada.
Even after the disastrous earnings report, management was typically in denial.
“We are pleased with our second quarter results and strong business momentum,” said Brendan Kennedy, Tilray President and Chief Executive Officer. “Our team has executed against our plan, with adult-use revenue nearly doubling in the second quarter compared to the first quarter and gross margin increasing sequentially for the second quarter in a row. As we continue to grow, we remain focused on our long-term strategic objectives and deploying capital to maximize stockholder value.”
The trading tape continues to be characterized by a pretty dominant offer, which hasn’t been the type of action TLRY shareholders really want to see. In total, over the past five days, shares of the stock have dropped by roughly -11% on above average trading volume. All in all, not a particularly friendly tape, but one that may ultimately present some new opportunities.
Tilray Inc (NASDAQ:TLRY) managed to rope in revenues totaling $45.9M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 371.1%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($220.9M against $175.9M).
But, in all of this, losses continue to pile up much faster than anticipated and the convertible debt servicing undermines that sense of a superficially strong balance sheet.
Medicine Man Technologies Inc (OTCMKTS:MDCL) generated sales of $1.8M, according to information released in the company’s most recent quarterly financial report. In addition, the company is sitting on about $4.3M in cash. That puts the stock in a sweet spot as far as valuation in the pot space, with shares trading at around 14x sales.
That sense has fueled aggressive interest in the name, with shares rallying as much as 30% higher so far during September alone.
As we have noted in the past, the company is capitalizing on recent changes in Colorado state law (namely, passage of HB 19-1090, which will take effect on November 1, and allow for outside investors, venture capitalists and private equity firms to gain investment access to Colorado’s cannabis industry.
MDCL has been a well-respected and successful advisor and consultant to firms in the cannabis industry for many years. But this shift in the legal context has created a new opportunity to consolidate production and distribution under the MDCL umbrella in a roll-up that could produce significant revenue growth for a stock that is already cheap relative to peers in the space.
Here’s the company’s CEO on the new bill: “At a time when cannabis is valued at $1.5 billion and is expected to grow to $2.1 billion by 2022 in Colorado alone, this legislation will serve to accelerate Colorado’s leadership position in the entire cannabis industry, and those entities fortunate enough to do business in our state – including our own. This was a tremendous win for the industry and for Medicine Man Technologies.”
In all, the company has entered into binding term sheet agreements to roll up some bread and butter in the Colorado cannabis marketplace, including 12 cultivation facilities, 7 proprietary extraction facilities, 7 manufacturers of infused products, 33 strategically located retail dispensaries, and a state-of-the-art manufacturing, research and development lab that represents Colorado’s first and only active cannabis research license in the state.
OrganiGram Holdings Inc (NASDAQ:OGI) recently announced that it has received Health Canada’s approval for the licensing of 17 additional cultivation rooms under the Cannabis Regulations.
According to the release, the new cultivation rooms represent approximately 15,000 kg/yr1 of increased target production capacity. These are the first 17 rooms licensed within the Company’s Phase 4B expansion and now brings the Company’s Moncton facility to annualized licensed capacity to a target of 76,000 kg. The licenses are valid until March 27, 2020 and subject to terms and conditions.
“Once again, we are pleased to receive licensing approval consistent with our expectations and the streamlined process we have experienced to date. Our Phase 4 facility expansion remains on schedule to meet growing demand and further contribute to efficiencies of scale,” explains Greg Engel, CEO, Organigram.
OrganiGram Holdings Inc (NASDAQ:OGI) promulgates itself as a company that, through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada.
It also offers wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis oils to retailers and wholesalers. The company also exports its products. It sells its products online, as well as through phone orders. OrganiGram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
Even with that news, the action hasn’t really heated up in the stock, with shares moving net lower over the past week.
OrganiGram Holdings Inc (NASDAQ:OGI) pulled in sales of $24.8M in its last reported quarterly financials, representing top line growth of 564.3%. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($87.8M against $25.7M).
Friday, September 27th, 2019UncategorizedComments Off on $OGI Comparing Leading Cannabis Stocks in a Stockpicker’s World
Predictive Oncology (NASDAQ: POAI) is assisting clinicians and researchers in improving outcomes for cancer patients via its AI-driven, tumor-profiling platform. A recent article discussing the company reads, “POAI’s technology combines its database of evidence documenting actual drug responses of cancer patients’ tumors with artificial intelligence (AI) to create an invaluable predictive tool for clinicians and researchers. Predictive Oncology’s data offers a valuable, customizable assessment method that can be used by oncologists to determine the best drug for fighting a specific patient’s cancer. This disruptive technology is the first of its kind and is also meeting a critical need in the pharmaceutical, diagnostic and biotech industries to speed up the search for new precision therapies by providing tools to better predict how new drugs work on different cancers (http://nnw.fm/B4htL). . . . POAI’s wholly owned subsidiaries — Helomics and TumorGenesis — are working together to bring these important precision-medicine tools to physicians.”
Predictive Oncology (formerly Precision Therapeutics Inc.) operates through its three business units: Helomics, TumorGenesis and Skyline Medical. Helomics applies artificial intelligence to rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient-treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision-oncology platform, Helomics offers boutique CRO services that leverage its TruTumor, patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D-CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences, Inc. (OTCQB: PBIO) is engaged in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, according to the company’s website (click here: www.pressurebiosciences.com). SNNLive caught up with Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. at RHK Capital’s 2019 Disruptive Growth Company Showcase in New York City, NY, and they discuss the following topics:
The interview may contain forward looking statements about Pressure BioSciences, Inc. See Pressure BioSciences’ periodic filings with the Securities and Exchange Commission for more complete information.
COLUMBUS, OH, Sept. 26, 2019 – Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) (“GGB” or “the Company”) is pleased to announce that Jann Parish, Chief Marketing Officer, has been named to the Forbes CMO Next list. The list is comprised of 50 individuals who are leading the way as disruptive chief marketers.
Through qualitative research tapping into the expertise of industry watchers as well as Forbes‘ editorial industry knowledge, the list features 50 people who have reached the highest-level marketing position within a given company and who are driving brand and business growth.
“I am honored and humbled to receive this recognition,” said Jann Parish, CMO of Green Growth Brands. “I am thrilled to be applying my expertise to the cannabis and CBD industries. At Green Growth Brands, we look at this moment in time as an opportunity to reinvent the way consumers view and interact with products that have very complicated histories. For Forbes to be considering our industry as part of this award speaks to the progress we have already made.”
“Jann has experience growing and redefining some of the most iconic global brands,” said Peter Horvath, CEO of Green Growth Brands. “Her vision and leadership are pivotal to our strategy— creating the new standard of cannabis and CBD consumer experiences. We are thrilled for her and the well-deserved recognition.”
Through Parish’s leadership GGB has opened over 130 Seventh Sense CBD shops across the U.S., grown Seventh Sense’s digital reach, prepared for the October launch of new CBD brand, Green Lily and increased sales and margin figures in its Nevada The+Source dispensary business by double digits.
About Green Growth Brands Inc. Green Growth Brands creates remarkable experiences in cannabis and CBD. Led by CEO Peter Horvath and a leadership team of consumer-focused retail experts, the company’s brands include CAMP, Seventh Sense Botanical Therapy, The+Source, Green Lily, and Meri + Jayne. The Company also has a licensing agreement with the Greg Norman™ Brand to develop a line of CBD-infused personal care products designed for active wellness. Already driving the strongest sales per square feet in the cannabis industry, GGB is expanding its cannabis operations throughout the U.S its CBD presence at ShopSeventhSense.com, in malls across the country, at DSW and Abercrombie & Fitch stores—and that’s just the beginning. Learn more about the vision at GreenGrowthBrands.com.
Cautionary Statements:
Certain information in this news release constitutes forward-looking statements under applicable securities law. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “intend”, “forecast” and similar expressions. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the marijuana industry in the United States, income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; currency and interest rate fluctuations and other risks, including those factors described under the heading “Risks Factors” in the Company’s Annual Information Form dated November 26, 2018, which is available on the Company’s issuer profile on SEDAR.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this release, including, but not limited to, the Company’s ability to execute on its growth strategy, the Company’s vision to become a multi-state operator with retail stores exceeding certain financial thresholds is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
This announcement does not constitute an offer, invitation or recommendation to subscribe for or purchase any securities and neither this announcement nor anything contained in it shall form the basis of any contract or commitment. In particular, this announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal.
The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the Securities Act or an exemption from the registration requirements of the Securities Act is available.
Thursday, September 26th, 2019UncategorizedComments Off on $GGBXF Jann Parish Named to Forbes CMO Next List
TORONTO, Sept. 26, 2019 – Canopy Rivers Inc. (“Canopy Rivers” or the “Company“) (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, today announced the voting results from its annual general and special meeting of shareholders (the “Meeting“) held today.
32,117,069 of the Company’s issued and outstanding subordinated voting shares (each carrying one vote per share) and 36,468,318 of the Company’s issued and outstanding multiple voting shares (each carrying 20 votes per share), representing 86.14% of the votes attached to all outstanding shares of the Company, were represented in person or by proxy at the Meeting.
Shareholders voted in favour of each of the items of business before the Meeting, including the election of each of the director nominees to serve until the Company’s next annual shareholders’ meeting or until his or her successor is duly elected or appointed. The results are set out below:
Name of Director
Nominee
Votes cast
FOR
% votes cast
FOR
Votes
WITHHELD
% votes
WITHHELD
Narbe Alexandrian
754,140,044
99.96%
328,582
0.04%
John K. Bell
748,580,962
99.22%
5,887,664
0.78%
Asha Daniere
754,026,441
99.94%
442,185
0.06%
Richard Mavrinac
754,043,067
99.94%
425,559
0.06%
Joseph Mimran
754,155,065
99.96%
313,561
0.04%
For detailed voting results on each matter, please refer to the Company’s Report of Voting Results available under the Company’s profile on SEDAR at www.sedar.com.
About Canopy Rivers: Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers identifies strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.
Thursday, September 26th, 2019UncategorizedComments Off on $CNPOF $RIV.V Announces Results of Annual General and Special Meeting of Shareholders
The UK government has legalized the use of medical marijuana; however, accessing it is next to impossible. This has prompted professors, doctors, health experts, and politicians to sign letters petitioning the government to make medical marijuana free to all patients. To access medical marijuana for free, patients have to present a prescription from the NHS (National Health Service), which serves as the United Kingdom’s comprehensive, universal, and free-at-the-point-of-service system of medication.
It is legal to prescribe medical cannabis under particular conditions on the NHS system; however, there exist several restrictions and obstacles that hinder specialists from prescribing medical marijuana treatment to patients. The letter signed by the pharmacists, health experts, and members of parliament appeals to the UK Health Secretary Matt Hancock to lift these restrictions. The Members of Parliament representing the Liberal Democrats and Labour have also signed a letter to the Prime Minister, Boris Johnson, appealing to him to intervene for the patients who are unable to access medical marijuana prescriptions.
Doctors and politicians are ready to change the highly restrictive measures administered by the UK government regarding legal access to medical cannabis. The UK government system governing access to medical marijuana does not give access to those patients who highly need it, thus causing unnecessary deaths and addiction to painkillers which could be avoided by treating the patient with medical cannabis.
In their letter to Mr. Hancock, the health experts argue that the failure of the medical and pharmacy professions to embrace medical cannabis is the leading cause of death from conditions that could be prevented, such as epilepsy.
A recent study by Public Health England concludes that a quarter of the population, ‘mainly adults’ consume strong painkillers, sleeping aids and antidepressants. The conditions forcing them to take these medications could be effectively and safely treated using medical marijuana.
Health experts in the UK want these restrictions lifted because it would make it easier for the doctors to prescribe medical cannabis for treatment using the NHS system. They want Hancock to scrape off the rule requiring a senior doctor to sign off on a prescription and allow a general specialist to write medical marijuana prescriptions. Besides, they want the laws governing the importation of medical marijuana simplified.
The proposed changes to medical marijuana could improve the lives of many patients because with a prescription from the medical provider; patients can access medical cannabis freely. Lack of access to medical cannabis prescription forces patients to seek the help of private caregivers who are very expensive; forcing the patients to turn to the use of unregulated weed for relief.
For the long term effect of free medical marijuana to be seen, professors, health experts and MPs advocate for the training of doctors on medical cannabis treatment and the process of prescribing. Medical cannabis should be prescribed to patients suffering from chronic pain, epilepsy, cancer, multiple sclerosis, depression and insomnia.
In response to the letter, NICE (National Institute for Health and Care Excellence) is opposed to the use of medical marijuana, citing lack of enough clinical evidence.
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW420? Ask our Editor
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that its patented pressure cycling technology (“PCT”) platform was prominently featured at the International Human Proteome Organization World Congress (“International HUPO”) in no less than ten separate presentations from scientists affiliated with seventeen leading research institutions worldwide. “We believe the unique value provided by our PCT platform for cancer research and diagnostics, which was broadly highlighted across ten presentations at this important international human protein conference, will help to accelerate awareness and adoption for our unique PCT sample preparation platform across multiple large and growing markets. Subsequently, we believe this increased awareness and conversion into adoption will result in increased sales of our PCT instruments and consumables in Q4 2019 and beyond,” Pressure BioSciences Global Director of Sales & Marketing Roxana McCloskey stated in the news release.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://nnw.fm/PBIO
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
The biggest marijuana day of the year is exactly three weeks away. On Oct. 17, 2019, marking the one-year anniversary since recreational marijuana sales commenced in Canada, rules governing the sale of derivative pot products will officially go into effect. However, new products won’t hit dispensary store shelves until about two months later.
Derivatives are non-dried-flower marijuana products. Examples include edibles, concentrates, vapes, topicals, and nonalcoholic infused beverages. Prior to Oct. 17, 2019, only dried cannabis flower, cannabis oil, and sublingual sprays were given the green light by regulatory agency Health Canada.
The excitement surrounding the launch of derivatives is easy to wrap your hands around as an investor or business operator in the cannabis space for one simple reason: the margins are juicier. In select recreationally legalized U.S. markets, the oversupply and eventual commoditization of dried flower has led to a steady decline in per-gram dried cannabis pricing, as well as margins. That oversupply concern simply doesn’t exist in the derivatives space.
Furthermore, derivatives tend to speak to a newer generation of marijuana-product consumers. With tobacco health concerns better known after decades of research, younger pot users prefer consumption options that don’t involve smoking dried flower. That’s where derivative pot products come into play.
Among the many alternative consumption options available, perhaps none has attracted more attention from brand-name cannabis stocks and ancillary players than infused beverages. Though there are no shortage of companies angling for their piece of the pie, the following three cannabis stocks are the ones you’ll want to know.
Canopy Growth
Canopy Growth (NYSE:CGC) is not only the largest marijuana stock in the world by market cap, but it’s liable to be one of the largest players in the infused beverage business. That distinction is the result of a massive equity investment from Corona and Modelo beer-maker Constellation Brands (NYSE:STZ) that closed in November.
The investment made by Constellation gave the company a 37% stake in Canopy Growth. Obviously, Constellation sees more in Canopy than just partnering up on a line of infused beverages; otherwise, it wouldn’t have taken a cumulative $4.2 billion equity stake and purchased approximately $150 million in convertible notes between Oct. 2017 and Nov. 2018. Nevertheless, Constellation Brands is looking for ways to naturally expand its reach into other vice industries, and cannabis is a natural evolution, according to its management team.
This partnership will allow Constellation and Canopy to bring their unique perspectives to the table in creating a line of infused cannabis beverages. Namely, Canopy will be leaned on for its expertise in cannabis, as well as its branding strengths and ability to land substantive supply deals. Meanwhile, Constellation Brands has a history of successful marketing, product innovation, and boasts deep pockets.
It’s unclear how much of a needle mover infused beverages will be for Constellation in the quarters to come, but it should be a difference maker for Canopy Growth.
OrganiGram Holdings
The thing about the cannabis industry is that businesses don’t need to be the size of Canopy Growth to be wildly successful at certain niches. New Brunswick-based OrganiGram Holdings (NASDAQ:OGI), which sports a roughly $650 million market cap, is a perfect example.
OrganiGram is focused on a slew of derivative options. It’s one of four suppliers chosen by PAX Labs for the Era vape device, and the company has spent 15 million Canadian dollars on a line of fully automated equipment that will allow for the production of 4 million kilos of infused chocolates each year. But the most intriguing aspect of OrganiGram’s derivatives line might just be its nano-emulsion technology that’s focused on beverages.
Earlier this year, OrganiGram announced that it had developed a nano-emulsification technology that can be added to beverages to speed up the process by which cannabinoids take effect. The company plans to introduce this technology first as a powder that users can add to an infused beverage of their choosing.
However, OrganiGram has also made clear that it would like to develop a line of infused cannabis beverages with this proprietary technology already built in. It’s been actively looking for a beverage partner to help develop and market a nano-emulsification beverage product, and I’d be genuinely surprised if it failed to find one relatively soon.
HEXO
A third brand-name Canadian pot stock that you’ll want to closely monitor as infused beverages begin to roll out is Quebec-based HEXO (NYSE:HEXO).
Even though Constellation’s $190 million equity investment into Canopy in Oct. 2017 marked the first foray of a major company into the cannabis space, it’s the joint venture between HEXO and Molson Coors Brewing (NYSE:TAP), announced on Aug. 1, 2018, that truly signaled a definitive focus on marijuana products between a brand-name company and a pot stock.
The joint venture, known as Truss, is majority-owned by Molson Coors (57.5% to 42.5%). As with the Constellation-Canopy equity investment, Molson and HEXO plan to lean on each other’s expertise to market their infused beverages. HEXO has keen knowledge of growing and processing marijuana, as well as landing major supply deals. Meanwhile, Molson Coors understands how to market beverage products and scale production.
Because Molson Coors is generating more than $10 billion annually in sales, it’s unclear how much of an impact infused beverages will have on its top or bottom line. But given its persistent decline in beer market share in Canada, partnering with a brand-name cannabis stock was a must for Molson Coors.
HEXO, on the other hand, should see an even more impactful increase on its sales from beverages than Canopy Growth. Look for 2020 to be a year of impressive sales and margin expansion for HEXO.
Thursday, September 26th, 2019UncategorizedComments Off on $OGI 3 Brand-Name Cannabis-Infused Beverage Stocks You Need to Know
NEW YORK, Sept. 26, 2019 — via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers.”
Treatment for breast cancer varies, based on both the patient’s circumstances and type of cancer. The development of treatments to suppress or even eliminate cancer has led to a high survival rate in wealthy countries, with around 85% of patients in the United States and United Kingdom surviving for at least five years from diagnosis. But even in these countries, survival depends upon the exact form of the cancer, how far it has progressed and whether a treatment has been developed for that particular form. Cancer is a difficult disease to defeat, and survival can depend upon the ability of scientists to counter a specific genetic defect in a specific set of cells.
Because cancers are so varied and challenging to tackle, every individual win is worth celebrating. That’s why recent news relating to triple-negative breast cancer (TNBC) has brought excitement both for independent researchers and for Genprex Inc. (NASDAQ:GNPX), a clinical-stage, gene-therapy company whose tumor suppressor candidate 2 (TUSC2) was found to prevent tumor growth in TNBC.
About Genprex Inc.
Genprex Inc. is a clinical-stage, gene-therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell-signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at www.genprex.com or follow Genprex on Twitter at twitter.com/genprex, Facebook at facebook.com/genprexinc and LinkedIn at linkedin.com/company/genprex.
About NetworkNewsAudio
NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Youngevity International (NASDAQ: YGYI), a leading multi-channel lifestyle company operating in three distinct business segments, on Tuesday announced the closing of its underwritten public offering of 333,500 shares of its 9.75% Series D Cumulative Redeemable Perpetual Preferred Stock, including 43,500 shares pursuant to the exercise of the over-allotment option by the underwriters. The shares were sold at a public offering price of $25.00 each, resulting in gross proceeds of $8,337,500, prior to withholding discount, commissions and estimated offering expenses. The Benchmark Company, LLC acted as sole book-running manager of the offering.
In addition, YGYI this morning announced the launch of Hemp FX in Japan. Hemp FX is a phytocannabinoid-rich hemp oil product line that includes three proprietary formulas featuring full-spectrum, organically grown hemp oil. Hemp FX Soothe, Hemp FX Capsules and Hemp FX Tincture have obtained the applicable approvals and are now available for purchase in Japan. “Hemp FX is an ideal representation of our plant-based approach to product development. These select products are being offered in this initial launch, and we expect the Hemp FX line will continue to grow, with more products becoming available for sale in Japan in the near future,” Youngevity CEO Steve Wallach stated in the news release. “This product launch has really been creating excitement in the Japanese market and we expect that it will provide significant growth within our distributor base in Japan.”
Youngevity International Inc. is a multi-channel lifestyle company operating in three distinct business segments, including a commercial coffee enterprise, a commercial hemp enterprise and a multi-vertical omni direct selling enterprise. The company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity; YGYI offers products from the six top-selling retail categories, including health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry and innovative services. For more information, visit the company’s website at www.YGYI.com.
NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://nnw.fm/YGYI
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
The Green Organic Dutchman produces high-quality, organic cannabis for the medicinal and recreational adult use markets from purpose-built, state-of-the-art facilities
The company has confirmed higher demand for premium organic cannabis
TGOD has also announced positive results from its pharmacokinetic study of innovative cannabinoid technology
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is an international, premium organic cannabis company based in Mississauga, Ontario. The company produces high-quality, organic medical and recreational adult use cannabis using organic craft growing principles. TGOD plans on commercializing organic cannabinoid dissolvables in Canada beginning in December 2019 under the TGOD-Infusers line of premium cannabis products, and results from a recent study have given support to that move. Additionally, TGOD was able to report strong demand for its premium organic cannabis following its Ontario launch and fast-tracked shipments.
Following its Ontario launch and fast-tracked shipments, TGOD reported that there is a strong demand for its premium organic…
NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://nnw.fm/TGODF
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
LOS ANGELES, Sept. 25, 2019 — SRAX, Inc. (NASDAQ: SRAX), a digital marketing and consumer data management technology company, is scheduled to present at the 5th Annual B. Riley Consumer & Media Conference on Thursday, October 3, 2019, at the Sofitel Hotel in New York City.
CEO Chris Miglino will participate in a fireside chat with analyst Mike Crawford on October 3rd at 1:00 p.m. ET and will host one-on-one meetings with investors throughout the day. To schedule a meeting please contact your B. Riley representative.
About SRAX SRAX (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring revenue streams through its various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data thereby offering everyone in the Internet ecosystem choice, transparency, and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury, and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information on SRAX, visit www.srax.com
